Overview
Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour. Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V and V cellular receptors. The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock. It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.
Background
Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour. Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V and V cellular receptors. The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock. It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.
Indication
1.诊断和治疗由于缺乏抗利尿激素而引起的尿崩症,也用于其他药物效果不佳的腹部肌肉松弛; 2.脑外科手术后或头颅创伤后多尿的初期治疗; 3.用于食管、胃肠道消化道疾病的急性大出血的辅助治疗。
Associated Conditions
- Acute Circulatory Failure
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/03/04 | Phase 4 | Not yet recruiting | |||
2024/01/31 | Not Applicable | Recruiting | King's College Hospital NHS Trust | ||
2024/01/22 | Phase 4 | ENROLLING_BY_INVITATION | |||
2023/07/24 | Phase 2 | Recruiting | |||
2023/04/10 | Phase 4 | Recruiting | |||
2023/02/21 | Phase 1 | Recruiting | |||
2022/10/05 | Phase 3 | Recruiting | |||
2022/04/07 | Not Applicable | UNKNOWN | |||
2022/01/14 | Phase 4 | Withdrawn | |||
2021/05/18 | Not Applicable | Completed | University of Electronic Science and Technology of China |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Eugia US LLC | 55150-370 | INTRAVENOUS | 20 [USP'U] in 1 mL | 11/7/2023 | |
Par Pharmaceutical, Inc. | 42023-268 | INTRAVENOUS | 1 [USP'U] in 1 mL | 11/16/2023 | |
Par Pharmaceutical, Inc. | 42023-164 | INTRAVENOUS | 20 [USP'U] in 1 mL | 3/6/2023 | |
Baxter Healthcare Corporation | 0338-9640 | INTRAVENOUS | 20 [USP'U] in 100 mL | 9/29/2023 | |
Eugia US LLC | 55150-370 | INTRAVENOUS | 20 [USP'U] in 1 mL | 8/4/2023 | |
Par Pharmaceutical, Inc. | 42023-219 | INTRAVENOUS | 0.4 [USP'U] in 1 mL | 11/16/2023 | |
Par Pharmaceutical, Inc. | 42023-190 | INTRAVENOUS | 20 [USP'U] in 1 mL | 11/16/2023 | |
Par Pharmaceutical, Inc. | 42023-237 | INTRAVENOUS | 0.2 [USP'U] in 1 mL | 11/16/2023 | |
Baxter Healthcare Corporation | 0338-9647 | INTRAVENOUS | 40 [USP'U] in 100 mL | 9/29/2023 | |
Fresenius Kabi USA, LLC | 65219-039 | INTRAVENOUS | 20 [USP'U] in 1 mL | 7/1/2022 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |